Dong-A gets EU COS for epirubicin
Seoul, South Korea-based drugmaker Dong-A Pharmaceutical says that it has been granted the Certificate of Suitability of Monographs of the European Pharmacopeia (COS) for epirubicin HCl.
The compound, which is an active pharmaceutical ingredient used in some anticancer drugs to inhibit the synthesis of nucleic acids in tumor cells, is a second-generation version of the anticancer agent doxorubicin. The firm added that the two components can be used to treat the same kinds of breast, stomach and lung cancers, but that epirubicin HCl has an improved side effect profile.
The certificate, which indicates approval by the European Directorate for the Quality of Medicines (EDQM), also ensures that the material complies with the relevant section of the European Pharmacopeia. Dong A added that it intends to enter the European market with the compound in the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze